Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: Discordance rates and prognosis

World Journal of Surgical Oncology

Volumn 9, Issue , 2011, Pages

  Nishimura, Reiki ^a   Osako, Tomofumi ^a   Okumura, Yasuhiro ^a   Tashima, Rumiko ^a   Toyozumi, Yasuo ^a   Arima, Nobuyuki ^a  

^a KUMAMOTO CITY HOSPITAL   (Japan)

Author keywords

Biomarker; Breast cancer; Discordance; Ki 67

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; HER2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER RELAPSE; CANCER SURGERY; DISEASE FREE INTERVAL; DISTANT METASTASIS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; RECURRENT CANCER; ADULT; AGED; BREAST TUMOR; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80054053337     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-9-131     Document Type: Article

References (15)

1. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, . Panel members Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20(8):1319-29. 10.1093/annonc/mdp322, 2720818, 19535820, Panel members.
2. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998, 339:974-84. 10.1056/NEJM199810013391407, 9753714.
3. Wilking U, Skoog L, Elmberger G, Wilking N, Bergh J. HER2 gene amplification (HER2) and hormone receptor expression (ER/PR) in early (EBC) and metastatic breast cancer (MBC) in the same patients. J Clin Oncol 2007, 25(18 Suppl):1023.
4. Sari E, Guler G, Hayran M, Gullu I, Altundag K, Ozisik Y. Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol 2011, 28(1):57-63. 10.1007/s12032-010-9418-2, 20099049.
5. Amir E, Ooi WS, Simmons C, Kahn H, Christakis M, Popovic S, Kalina M, Chesney A, Singh G, Clemons M. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies. Clin Oncol (R Coll Radiol) 2008, 20(10):763-8.
6. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009, 20(9):1499-504. 10.1093/annonc/mdp028, 2731014, 19299408.
7. Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med 2010, 1:747-754.
8. Kai K, Nishimura R, Arima N, Miyayama H, Iwase H. p53 Expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol 2006, 11:426-33. 10.1007/s10147-006-0601-6, 17180510.
9. Montagna E, Bagnardi V, Rotmensz N, Viale G, Renne G, Cancello G, Balduzzi A, Scarano E, Veronesi P, Luini A, Zurrida S, Monti S, Mastropasqua MG, Bottiglieri L, Goldhirsch A, Colleoni M. Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol 2011,
10. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009, 20(12):1953-8. 10.1093/annonc/mdp263, 2791352, 19596702.
11. Locatelli MA, Curigliano G, Fumagalli L, Bagnardi V, Aurilio G, Della Vigna P, Monfardini L, Giudici S, Viale G, Goldhirsch A. Should liver metastases of breast cancer be biopsied to improve treatment choice?. J Clin Oncol 2010, 28:18s. (suppl; abstr CRA1008).
12. Dowsett M, Dunbier AK. Emerging Biomarkers and NewUnderstanding of TraditionalMarkers in Personalized Therapy for Breast Cancer. Clin Cancer Res 2008, 14(24):8019-8026. 10.1158/1078-0432.CCR-08-0974, 19088018.
13. Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer 2010, 17(4):269-75. 10.1007/s12282-009-0161-5, 19730975.
14. Tanei T, Shimomura A, Shimazu K, Nakayama T, Kim SJ, Iwamoto T, Tamaki Y, Noguchi S. Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol 2011, 37(2):155-61. 10.1016/j.ejso.2010.10.009, 21111561.
15. Falck A-K, Ferno M, Bendahl P, Rydén L. Does Analysis of Biomarkers in Tumor Cells in Lymph Node Metastases Give Additional Prognostic Information in Primary Breast Cancer?. World J Surg 2010, 34:1434-1441. 10.1007/s00268-010-0499-z, 20213203.